TI
TCRT icon

tru Independence’s Alaunos Therapeutics TCRT Stock Holding History

tru Independence’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,425
Closed -$701 – 797
2020
Q2 		$701 Sell
1,425
-441
-24% -$197K 0.1% 145
2020
Q1 		$686 Hold
1,866
– – 0.11% 120
2019
Q4 		$686K Buy
+1,866
New +$1.28M 0.1% 137

Other funds holding TCRT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

tru Independence's TCRT Position: Q3 2020 in Review

tru Independence sold out of Alaunos Therapeutics (TCRT) in Q3 2020, closing a stake of 1,425 shares — an estimated $701 sold.

tru Independence first reported a position in TCRT in Q4 2019 and held it in 3 quarters. The position peaked at $686K in Q4 2019. 154 funds tracked by Wall St. Rank hold TCRT as of Q3 2020.

  • tru Independence reported no remaining Alaunos Therapeutics position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 1,425 Alaunos Therapeutics shares in Q3 2020, an estimated $701.
  • tru Independence first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 3 quarters.
  • tru Independence's Alaunos Therapeutics position peaked at $686K in Q4 2019.
  • 154 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.